Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 20, 2025 (GLOBE NEW ...

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Sarepta investors affected by alleged securities fraud between June 22, 2023, and June 24, 2025 [1]. - The complaint claims that Sarepta made false statements regarding the safety of ELEVIDYS, including significant safety risks and failures in trial protocols to detect severe side effects [2]. - It is alleged that the adverse events from ELEVIDYS treatment could lead to a halt in recruitment and dosing in trials, increased regulatory scrutiny, and greater risks regarding the therapy's approvals [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential halting of recruitment and dosing, increased regulatory scrutiny, and risks to the therapy's approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4]

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, resulting in a stock price drop of over 40% on July 18, 2025 [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, to close at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although they can remain absent class members without taking action [5].

Core Viewpoint - Sarepta Therapeutics is facing a securities class action lawsuit due to safety concerns regarding its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy, following a negative assessment from European regulators [1][6][5]. Group 1: Regulatory Challenges - European drug regulators concluded that ELEVIDYS did not demonstrate clear benefits for patients, as a pivotal trial involving 125 children showed no significant difference in movement improvement compared to a placebo [3][4]. - The European Medicines Agency (EMA) cited concerns about the therapy's effectiveness and safety, ultimately determining that Sarepta did not provide sufficient evidence for broader approval [5]. Group 2: Legal Implications - A securities class action lawsuit alleges that Sarepta misled investors regarding the safety and efficacy of ELEVIDYS, claiming the company withheld critical information about significant safety risks [6][7]. - The lawsuit contends that disclosures about patient deaths during clinical trials led to a sharp decline in Sarepta's stock price, indicating that investors were not adequately informed about the risks associated with the drug [10][9]. Group 3: Investor Actions - The deadline for Sarepta investors who suffered losses to be considered as Lead Plaintiff in the class action is August 25, 2025, prompting a call for affected investors to submit their losses [2][3]. - Hagens Berman, the law firm leading the investigation, is looking into whether Sarepta's statements about ELEVIDYS were misleading in light of the recent findings from the EMA [12].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for adverse events to halt clinical trials and regulatory approvals [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317, with investors having until August 25, 2025, to seek lead plaintiff status [2]. Allegations - The complaint alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall by more than 40% on July 18, 2025 [5]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading international law firm specializing in securities class actions, is representing the plaintiffs in this case [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025 [1] Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3] - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which led to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS for Duchenne muscular dystrophy [3]. Allegations - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory requests for a review of the death, the stock price dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, caused the stock to plummet by $15.24 (42.12%) to close at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock fell by $1.52 (8.01%) to close at $17.46 [4].